| Literature DB >> 25946077 |
Paolo Ruzza1, Rohanah Hussain2, Barbara Biondi3, Andrea Calderan4, Isabella Tessari5, Luigi Bubacco6, Giuliano Siligardi7.
Abstract
Many neurodegenerative diseases, including Huntington's, Alzheimer's and Parkinson's diseases, are characterized by protein misfolding and aggregation. The capability of trehalose to interfere with protein misfolding and aggregation has been recently evaluated by several research groups. In the present work, we studied, by means of synchrotron radiation circular dichroism (SRCD) spectroscopy, the dose-effect of trehalose on α-synuclein conformation and/or stability to probe the capability of this osmolyte to interfere with α-synuclein's aggregation. Our study indicated that a low trehalose concentration stabilized α-synuclein folding much better than at high concentration by blocking in vitro α-synuclein's polymerisation. These results suggested that trehalose could be associated with other drugs leading to a new approach for treating Parkinson's and other brain-related diseases.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25946077 PMCID: PMC4496693 DOI: 10.3390/biom5020724
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Chemical structure of trehalose.
Figure 2Far-UV synchrotron radiation circular dichroism (SRCD) spectra of α-synuclein alone or in presence of 10 or 100 mM trehalose. α-Synuclein concentration was 0.36 mg/mL in PBS buffer, pH 7.4.
Figure 3Far-UV SRCD spectra of α-synuclein alone (a) or in presence of 10 mM (b) or 100 mM (c) trehalose at different temperature (indicated). α-Synuclein concentration was 0.36 mg/mL in PBS buffer, pH 7.4.
Figure 4CD melting curves of α-synuclein alone or in presence of 10 or 100 mM trehalose using biDoseResp curve fitting from OriginLab software with R2 of 0.98, 0.89 and 0.99 respectively.
Figure 5Secondary structure β-strand and unorder components melting curves of α-synuclein alone (a) or in presence of 10 mM (b) or 100 mM (c) trehalose.